PROTAC Market Shows Accelerated Growth During the Forecast Period (2025-2034) Amid Rising Targeted Therapy Demand | DelveInsight

Rhea-AI Summary

PROTAC market (coverage: 7MM) is forecast to grow sharply through 2034 as targeted protein degradation advances across oncology and other indications. Key pipeline assets include vepdegestrant, luxdegalutamide, ASP3082, and DT2216. The report cites ~90 protein-degradation leads, ~20% in clinical development, and PROTACs representing >30% of the protein degradation pipeline. Strategic partnerships include Arvinas collaborations with Pfizer and Novartis, and a Novartis up-front payment of USD 150 million for ARV-766 rights. Notable trial data: Phase III VERITAC-2 met its ESR1m primary endpoint but not the ITT population.

Positive

• Coverage of 7MM markets (US, EU4, UK, Japan)
• ~90 protein-degradation leads, with ~20% in clinical development
• Novartis paid USD 150M up front for ARV-766 rights
• Phase III VERITAC-2 met ESR1m primary endpoint for vepdegestrant

Negative

• No PROTAC therapy approved to date, so commercial risk remains
• VERITAC-2 failed to reach statistical significance in the ITT population

Key Figures

Metastatic breast with prior early-stage: Approximately 85% of patients Novartis upfront payment: USD 150 million Protein degradation leads: Nearly 90 leads +5 more

8 metrics

Metastatic breast with prior early-stage Approximately 85% of patients Share of metastatic breast cancer patients with earlier-stage diagnosis

Novartis upfront payment USD 150 million Upfront for rights to ARV-766 androgen receptor degrader

Protein degradation leads Nearly 90 leads Protein degradation–based leads currently under evaluation

Clinical-stage share Close to 20% Pipeline candidates in clinical development within protein degradation

PROTAC pipeline share More than 30% PROTAC share of all protein degradation pipeline drugs

Target Hazard Ratio HR 0.60 Pre-specified target exceeded for PFS in VERITAC-2 ESR1m population

Study period 2020–2034 Epidemiology and market forecast window in PROTAC report

Geographic coverage 7MM markets US, EU4, UK, and Japan PROTAC market coverage

Market Reality Check

Price: $13.44 Vol: Volume 43,621,305 vs 20-d...

normal vol

$13.44 Last Close

Volume Volume 43,621,305 vs 20-day average 56,190,954 (about 0.78x average activity) normal

Technical Price 27.61 is trading above 200-day MA at 24.75, showing a pre-news upward trend bias

Peers on Argus

PFE was down 0.62% with below-average volume, while large-cap peers like GILD (-...

1 Down

PFE was down 0.62% with below-average volume, while large-cap peers like GILD (-2.8%) and AMGN (-3.29%) also traded lower, indicating weakness in several drug makers but momentum scanner confirmation only for GILD.

Common Catalyst GILD had same-day dividend and earnings headlines, but no common PROTAC- or TPD-specific theme across peers.

Historical Context

5 past events · Latest: Feb 06 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 06	Regulatory priority review	Positive	+2.8%	FDA Priority Review for HYMPAVZI sBLA in hemophilia populations.
Feb 05	Access/pricing initiative	Positive	+2.8%	Launch of TrumpRx cost-savings program on 30+ branded medicines.
Feb 03	Earnings and guidance	Positive	-3.3%	Full-year 2025 results and reaffirmed 2026 revenue and EPS guidance.
Feb 03	Clinical trial update	Positive	-3.3%	Positive Phase 2b GLP-1 RA obesity data with significant weight loss signal.
Jan 07	Litigation update	Negative	-0.6%	MDL trial date set related to Depo-Provera litigation against Pfizer.

Pattern Detected

Recent regulatory and pipeline positives often saw mixed price reactions, with some strong news aligning with gains and others coinciding with selloffs.

Recent Company History

Over the past month, PFE has reported multiple catalysts, including a Priority Review for HYMPAVZI in hemophilia (Feb 6, 2026) and a broad cost-savings program on TrumpRx (Feb 5, 2026), both followed by +2.76% moves. Earlier, full-year 2025 results and positive GLP-1 Phase 2b data on Feb 3, 2026 coincided with a -3.34% reaction. A Depo-Provera MDL trial date on Jan 7, 2026 aligned with a modest -0.59% decline, showing that litigation headlines have weighed slightly on shares.

Market Pulse Summary

This announcement highlights the expanding PROTAC and targeted protein degradation market, emphasizi...

Analysis

This announcement highlights the expanding PROTAC and targeted protein degradation market, emphasizing assets linked to Pfizer such as vepdegestrant and broader collaborations in oncology. The report’s 2020–2034 horizon and coverage of 7MM markets frame PROTACs as a long-term modality rather than an immediate revenue driver. Investors may track future clinical milestones, partnering terms, and regulatory outcomes to gauge how much value this platform could ultimately contribute.

Key Terms

protac, targeted protein degradation, e3 ubiquitin ligase, progression-free survival, +2 more

6 terms

protac medical

"The PROTAC market is experiencing rapid growth, driven by rising interest"

A PROTAC (proteolysis targeting chimera) is a small engineered molecule that tags a specific protein inside cells and brings it to the cell’s disposal machinery so the protein is destroyed rather than just blocked. Think of it as a targeted cleanup crew that removes a problematic part instead of temporarily turning it off. Investors care because PROTACs can tackle disease targets that traditional drugs cannot, creating potential for breakthrough therapies, larger markets, and binary clinical readouts that can sharply affect company value.

targeted protein degradation medical

"Targeted Protein Degradation (TPD) is an emerging therapeutic modality"

Targeted protein degradation is a drug approach that uses small molecules to mark harmful or malfunctioning proteins inside cells so the cell’s own disposal system breaks them down, rather than simply blocking their activity. For investors, it matters because this method can potentially tackle diseases that traditional drugs cannot reach, offering a new class of therapies with broad commercial and patent potential—like switching from silencing a problem to removing it entirely.

e3 ubiquitin ligase medical

"bind a target protein and an E3 ubiquitin ligase, bringing the two into close proximity"

An e3 ubiquitin ligase is a specialized enzyme that acts like a labeler, attaching small protein tags called ubiquitin to other proteins to mark them for disposal or to change how they behave. For investors, these enzymes matter because they control biological pathways tied to disease and aging, making them attractive drug targets or diagnostic markers; therapies that boost or block specific e3 ligases can create new treatment opportunities and commercial value.

progression-free survival medical

"showing a significant improvement in progression-free survival (PFS) compared to"

Progression-free survival is the length of time during and after a treatment that a patient's disease does not get worse, measured from the start of treatment until the disease shows measurable signs of progression or the patient dies. Investors care because longer progression-free survival in clinical trials often signals that a drug is effective, improving chances of regulatory approval, market adoption, and revenue potential—think of it as a stopwatch showing how long a therapy can keep the illness at bay.

hazard ratio medical

"exceeding the pre-specified target Hazard Ratio (HR) of 0.60"

A hazard ratio is a way scientists compare the chance of something happening over time between two groups, like patients taking different medicines. If the ratio is high, it means one group is more likely to experience the event sooner or more often, which helps determine how effective a treatment is or how risky a situation might be.

phase ii clinical trial medical

"ARV-766 is currently being evaluated in a Phase II clinical trial for"

A Phase II clinical trial is a mid-stage study in humans that tests whether an experimental drug or treatment actually works and what dose is effective, typically involving dozens to a few hundred patients and often comparing outcomes to a placebo or standard care. For investors, Phase II results are a major inflection point: clear positive data can substantially increase the odds of later regulatory approval and company value, while negative or uncertain results raise development risk and can sharply reduce expectations—like a detailed test drive after basic safety checks.

AI-generated analysis. Not financial advice.

The PROTAC market is experiencing rapid growth, driven by rising interest in targeted protein degradation as a next-generation therapeutic approach. Expanding oncology pipelines with drugs in clinical trials such as vepdegestrant (Arvinas and Pfizer), luxdegalutamide (Arvinas and Novartis), ASP3082 (Astellas Pharma), DT2216 (Dialectic Therapeutics), and others, along with increasing applicability in neurodegenerative and inflammatory diseases, are further fueling sustained R&D investment.

LAS VEGAS, Feb. 10, 2026 /PRNewswire/ -- DelveInsight's PROTAC Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as HR+/HER2− Breast Cancer, Triple Negative Breast Cancer (TNBC), Metastatic Castration-resistant Prostate Cancer, Colorectal Cancer, Non-small Cell Lung Cancer (NSCLC), and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging PROTAC, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).

Key Takeaways from the PROTAC Market Report

• The total market size of PROTAC in the leading markets is expected to surge significantly by 2034.
• The report provides the total potential number of patients in the indications, such as HR+/HER2− Breast Cancer, Triple Negative Breast Cancer (TNBC), Metastatic Castration-resistant Prostate Cancer, Colorectal Cancer, Non-small Cell Lung Cancer (NSCLC), and others.
• Approximately 85% of patients diagnosed with metastatic breast cancer have had an early-stage breast cancer diagnosis. However, most patients with early-stage breast cancer do not go on to develop metastatic disease.
• Leading PROTAC companies, such as Arvinas (NASDAQ: ARVN), Pfizer (NYSE: PFE), Novartis (SWX: NOVN), Astellas Pharma (TYO: 4503), Dialectic Therapeutics, and others, are developing novel PROTAC that can be available in the PROTAC market in the coming years. 
• Some of the key PROTACs in clinical trials include Vepdegestrant, Luxdegalutamide, ASP3082, DT2216, and others.

Discover PROTAC market CAGR and revenue projections @ https://www.delveinsight.com/sample-request/protac-market-forecast?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr

Key Factors Driving the PROTAC Market 

• High Therapeutic Potential and Mechanism of Action: PROTACs offer a novel mechanism that selectively degrades disease-causing proteins rather than simply inhibiting them. This expands therapeutic possibilities, especially for targets previously considered "undruggable", boosting industry and investor interest.
• Rising Prevalence of Target Diseases: The increasing global burden of complex diseases, such as breast cancer, TNBC, mCRPC, colorectal cancer, NSCLC, and others, fuels the demand for innovative treatment options. PROTACs' ability to target pathogenic proteins drives research and clinical investment.
• Next-Generation AR Degradation in Mutant Androgen Receptor–Driven Prostate Cancer: Prostate cancer is traditionally treated with anti-androgen medications. However, PROTACs such as ARV-766 are thought to be effective in patients with AR that has mutated, particularly through a resistance mechanism such as L702H. ARV-766 has a superior and expanded efficacy profile and an improved tolerability profile compared with bavdegalutamide.
• Pharmaceutical Partnerships and Licensing Landscape: Opportunities for clinical collaboration and licensing with large pharmaceutical companies are presented here. Novartis paid USD 150 million up front, primarily for the rights to Arvinas's androgen receptor degrader ARV-766, thereby providing the company a second endorsement of its degradation strategy. It is important to note that Pfizer is already a partner with Arvinas for the PROTAC vepdegestrant.
• Emerging PROTAC Drugs in Development: Some of the potential drugs in the pipeline include vepdegestrant (Arvinas and Pfizer), luxdegalutamide (Arvinas and Novartis), ASP3082 (Astellas Pharma), DT2216 (Dialectic Therapeutics), and others.

PROTAC Market Analysis

• Targeted Protein Degradation (TPD) is an emerging therapeutic modality with the potential to target disease-causing proteins that have historically been difficult to reach with conventional small molecules.
• PROTACs are a key class of targeted protein degradation technologies, and over the past 20 years, the concept of harnessing the ubiquitin–proteasome system has evolved from academic research into active industry-led drug development.
• Nearly 90 protein degradation–based leads are currently under evaluation, with close to 20% of pipeline candidates in clinical development and the remainder in preclinical or discovery stages.
• PROTACs account for more than 30% of all protein degradation pipeline drugs, underscoring their growing prominence in this therapeutic space.
• The PROTAC market is expected to expand significantly in the coming years, driven by the rising number of PROTAC-designed molecules entering clinical trials, despite the absence of any approved therapies to date.
• The first PROTAC molecule, ARV-110, entered clinical testing in 2019, marking a major milestone for the modality.
• In 2020, early clinical data provided the first proof-of-concept for PROTACs against well-established cancer targets, including the estrogen receptor (ER) and androgen receptor (AR).
• Pfizer, in collaboration with Arvinas, is currently evaluating vepdegestrant in clinical trials as both a monotherapy and in combination regimens for ER+/HER2- breast cancer and other indications.
• Several major players, including Arvinas and Pfizer (Vepdegestrant), Arvinas and Novartis (Luxdegalutamide), Astellas Pharma (ASP3082), Dialectic Therapeutics (DT2216), and others, are advancing PROTAC-based therapies across multiple oncology indications such as ER+/HER2- breast cancer and metastatic prostate cancer.
• Overall, PROTACs represent an exciting and rapidly maturing class of therapeutic agents, with ongoing and future studies expected to clarify their clinical role in cancer and other diseases.

Learn more about PROTACs in oncology vs other indications @ PROTAC Analysis

PROTAC Competitive Landscape

Emerging players such as Arvinas and Pfizer (Vepdegestrant), Arvinas and Novartis (Luxdegalutamide), Astellas Pharma (ASP3082), Dialectic Therapeutics (DT2216), and others are evaluating drugs in clinical trials.

Arvinas and Pfizer's Vepdegestrant is an investigational, orally bioavailable PROTAC-based protein degrader engineered to selectively eliminate the estrogen receptor and is being developed for the treatment of ER+/HER2– breast cancer. In July 2021, Arvinas entered into a global partnership with Pfizer to jointly develop and commercialize vepdegestrant, with the two companies sharing worldwide development costs, commercialization expenses, and profits.

Arvinas and Novartis' ARV-766 is an investigational, orally bioavailable PROTAC protein degrader designed to selectively target and degrade the androgen receptor. In preclinical studies, ARV-766 has shown activity across models expressing wild-type androgen receptor as well as tumors harboring androgen receptor mutations or amplification, key mechanisms associated with resistance to existing androgen receptor–directed therapies. ARV-766 is currently being evaluated in a Phase II clinical trial for metastatic prostate cancer. In April 2024, Arvinas entered into an exclusive global licensing agreement with Novartis for the development and commercialization of ARV-766. The transaction also included an asset purchase agreement under which Novartis acquired Arvinas' preclinical AR-V7 program.

Astellas Pharma's ASP3082 is a PROTAC molecule that selectively degrades the KRAS G12D protein and represents the first targeted protein degrader to advance into clinical development for this target. It has the potential to become a first-in-class therapy for solid tumors driven by KRAS G12D mutations. A Phase I clinical trial is currently ongoing in patients with KRAS G12D–mutant solid tumors, with proof-of-concept data expected in the first half of calendar year 2025. The company is preparing to advance the program into registration trials.

The anticipated launch of these emerging therapies are poised to transform the PROTAC market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the PROTAC market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

To know more about pipeline PROTAC drugs and commercial potential, visit @ PROTAC Treatment 

Recent Developments in the PROTAC Market

• In November 2025, Arvinas presented multiple abstracts on vepdegestrant at the San Antonio Breast Cancer Symposium (SABCS).
• In October 2025, Arvinas announced new patient-reported outcomes data from the Phase III VERITAC-2 clinical trial evaluating vepdegestrant, which are being presented in a mini oral session at the 2025 European Society for Medical Oncology (ESMO) Congress.
• In March 2025, Arvinas and Pfizer announced positive topline results from the Phase III VERITAC-2 trial, which met its primary endpoint in the ESR1m population, showing a significant improvement in progression-free survival (PFS) compared to fulvestrant, exceeding the pre-specified target Hazard Ratio (HR) of 0.60. However, the trial did not reach statistical significance in the intent-to-treat (ITT) population. 

What are PROTACs?

PROTACs (PROteolysis TArgeting Chimeras) are an emerging class of therapeutic molecules designed to selectively degrade disease-causing proteins rather than merely inhibiting them. They are heterobifunctional compounds that simultaneously bind a target protein and an E3 ubiquitin ligase, bringing the two into close proximity and triggering ubiquitination of the target protein. This process marks the protein for destruction by the cell's natural proteasome system. By eliminating the protein entirely, PROTACs can achieve deeper and more sustained biological effects, overcome resistance seen with traditional inhibitors, and enable targeting of previously "undruggable" proteins. As a result, PROTAC technology is gaining significant traction across oncology, immunology, and other therapeutic areas.

PROTAC Epidemiology Segmentation

The PROTAC market report is a comprehensive and specialized analysis, offering in-depth epidemiological insights for the study period 2020–2034 across the leading markets. The PROTAC target patient pool is segmented into:

• Total Cases of Selected Indications for PROTAC
• Total Eligible Patient Pool for PROTAC in Selected Indications
• Total Treated Cases in Selected Indications for PROTAC

PROTAC Report Metrics	Details
Study Period	2020–2034
PROTAC Report Coverage	7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Key Indications Covered in the Report	HR+/HER2− Breast Cancer, Triple Negative Breast Cancer (TNBC), Metastatic Castration-resistant Prostate Cancer, Colorectal Cancer, Non-small Cell Lung Cancer (NSCLC), and others
PROTAC Target Patient Pool Segmentation	Total Cases of Selected Indications for PROTAC, Total Eligible Patient Pool for PROTAC in Selected Indications, and Total Treated Cases in Selected Indications for PROTAC
Key PROTAC Companies	Arvinas (NASDAQ: ARVN), Pfizer (NYSE: PFE), Novartis (SWX: NOVN), Astellas Pharma (TYO: 4503), Dialectic Therapeutics, and others
Key PROTACs	Vepdegestrant, Luxdegalutamide, ASP3082, DT2216, and others

Scope of the PROTAC Market Report

• PROTAC Therapeutic Assessment: PROTAC' current marketed and emerging therapies
• PROTAC Market Dynamics: Conjoint Analysis of Emerging PROTAC Drugs
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, PROTAC Market Access and Reimbursement

Discover emerging technologies for PROTAC design @ PROTAC Clinical Trials

Table of Contents

1	PROTAC Market Key Insights
2	PROTAC Market Report Introduction
3	Executive Summary
4	Key Events
5	Epidemiology and Market Forecast Methodology
6	PROTAC Therapies Market Overview at a Glance
6.1	Clinical Landscape (Analysis by Molecule Type, Phase, and Route of Administration [RoA])
6.2	Market Share (%) Distribution by Indications of PROTAC Therapies in 2028
6.3	Market Share (%) Distribution by Therapies of PROTAC Therapies in 2036
7	Background and Overview
8	Treatment Guidelines
9	Epidemiology and Patient Population
9.1	Key Findings
9.2	Assumptions and Rationale: 7MM
9.3	Epidemiology Scenario in the 7MM
9.3.1	Total Cases of Selected Indications for PROTACs in the 7MM
9.3.2	Total Eligible Patient Pool for PROTACs in Selected Indications in the 7MM
9.3.3	Total Treated Cases in Selected Indications for PROTACs in the 7MM
10	Emerging PROTAC Drugs
10.1	Key Cross Competition
10.2	Vepdegestrant (ARV-471): Arvinas and Pfizer
10.2.1	Product Description
10.2.2	Other Development Activities
10.2.3	Clinical Development
10.2.3.1	Clinical Trial Information
10.2.4	Safety and Efficacy
10.2.5	Analyst's Views
10.3	Luxdegalutamide (ARV-766): Arvinas and Novartis
List to be continued…..
11	PROTAC Therapies Market: Seven Major Market Analysis
11.1	Key Findings
11.2	PROTAC Market Outlook
11.3	Conjoint Analysis
11.4	Key PROTAC Market Forecast Assumptions
11.5	Total PROTAC Market Size by Country in the 7MM
11.6	Total PROTAC Market Size by Indications in the 7MM
11.7	Total PROTAC Market Size by Therapies in the 7MM
11.8	The United States PROTAC Market Size
11.8.1	Total PROTAC Market Size by Indications in the United States
11.8.2	Total PROTAC Market Size by Therapies in the United States
11.9	EU4 and the UK PROTAC Market Size
11.1	Japan PROTAC Market Size
12	PROTAC Market Unmet Needs
13	PROTAC Market SWOT Analysis
14	KOL Views on PROTAC
15	PROTAC Market Access and Reimbursement
15.1	The United States
15.2	In EU4 and the UK
15.3	Japan
15.4	Summary and Comparison of Market Access and Pricing Policy Developments in 2025
15.5	Market Access and Reimbursement of PROTAC Therapies
16	Bibliography
17	PROTAC Market Report Methodology

Related Reports

Non-small Cell Lung Cancer Market

Non-small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NSCLC companies, including Daiichi Sankyo, AstraZeneca, Gilead Sciences, BieGene, AbbVie, Roche, Merck, Novartis, Pfizer, Takeda Pharmaceuticals, Eli Lilly, BerGenBio, GlaxoSmithKline, Duality Biologics, and others.

Metastatic Castration-Resistant Prostate Cancer Market

Metastatic Castration-Resistant Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key mCRPC companies including Sanofi, AstraZeneca, Astellas Pharma, Bayer, Novartis, Curium, Merck, Orion, Janssen Pharmaceutical, Pfizer, Exelixis, Ipsen Pharma, Takeda, AB Science, Lantheus, Eli Lilly, POINT Biopharma, Telix Pharmaceuticals, Tavanta Therapeutics, Jiangsu Hengrui Pharmaceuticals, Kangpu Biopharmaceuticals, Fusion Pharma, Merus, Bristol-Myers Squibb, Syntrix Pharmaceuticals, Promontory Therapeutics, Xencor, Taiho Pharmaceutical, Madison Vaccines, MacroGenics, Zenith Epigenetics, Modra Pharmaceuticals, Arvinas, Laekna Therapeutics, Blue Earth Therapeutics, Oncternal Therapeutics, Essa Pharma, Clarity Pharmaceuticals, BioNTech, DualityBio, Daiichi Sankyo, Fortis Therapeutics, ORIC Pharmaceuticals, Amgen, among others.

Colorectal Cancer Market

Colorectal Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key colorectal cancer companies, including Mirati Therapeutics, Exelixis, Enterome, Arcus Biosciences, Lyell Immunopharma, AstraZeneca, Novartis Pharmaceuticals, Surgimab, Numab Therapeutics, SOTIO Biotech, Amgen, Sichuan Baili Pharmaceutical, Qilu Pharmaceutical, Bristol-Myers Squibb, NGM Biopharmaceuticals, Takeda, PureTech, Pfizer, Kezar Life Sciences, Salubris, Biotherapeutics, and others.

Metastatic HR+/HER2− Breast Cancer Market

Metastatic HR+/HER2− Breast Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key metastatic HR+/HER2− breast cancer companies, including Merck, Arvinas, Olema Pharmaceuticals, Celcuity, Roche, AstraZeneca, Daiichi Sankyo, Eli Lilly, Sermonix Pharmaceuticals, Genentech, Veru Pharma, DualityBio, BioNtech, Evgen Pharma, Carrick Therapeutics, EQRx, G1 Therapeutics, Immutep, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur
info@delveinsight.com
+14699457679

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/protac-market-shows-accelerated-growth-during-the-forecast-period-20252034-amid-rising-targeted-therapy-demand--delveinsight-302683414.html

SOURCE DelveInsight Business Research LLP

FAQ

What does DelveInsight report say about PROTAC market size and coverage for 2025–2034?

The PROTAC market is forecast to grow significantly in the 7MM through 2034, driven by oncology pipelines. According to DelveInsight, the analysis covers the US, EU4, UK, and Japan and models patient populations and market size from 2020–2034.

Which PROTAC drugs and partnerships are highlighted involving Pfizer (PFE)?

Vepdegestrant is highlighted as a Pfizer collaboration with Arvinas for ER+ breast cancer. According to DelveInsight, Pfizer and Arvinas share development costs and commercialization responsibilities for vepdegestrant.

What clinical result did Phase III VERITAC-2 report for vepdegestrant relevant to PFE shareholders?

VERITAC-2 met its primary endpoint in the ESR1m population, improving PFS versus fulvestrant. According to DelveInsight, the trial did not achieve statistical significance in the overall ITT population, creating mixed clinical readthroughs for commercialization.

How material is Novartis' deal for ARV-766 and what does it imply for the PROTAC market?

Novartis paid a USD 150 million up-front fee for ARV-766 rights, signifying commercial interest in PROTACs. According to DelveInsight, the transaction is a notable commercial endorsement of the targeted protein degradation approach.

What stage is Astellas' ASP3082 targeting KRAS G12D and expected proof-of-concept timing?

ASP3082 is in Phase I for KRAS G12D–mutant solid tumors with proof-of-concept expected in the near term. According to DelveInsight, the program aims to advance toward registration assuming positive early clinical data and development progress.

How large is the PROTAC development pipeline and what proportion is clinical versus preclinical?

The report cites nearly 90 protein-degradation leads, with roughly 20% in clinical development and the rest preclinical. According to DelveInsight, PROTACs represent over 30% of protein degradation pipeline candidates.